KOSDAQBiotech & Pharma087010

Peptron

₩130,300▼ 8.56%2026-10-02 close

Market Cap

₩3T

Turnover

₩27.1B

Volume

200,000 shares

Shares out.

23.3M

PER

—

PBR

28.2×

EPS

-₩883

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Lilly Evaluation Deadline and the New Plant: A Time for Verification

Peptron's market value rests not on revenue but on whether its SmartDepot platform converts into a full global license, and that decision window arrives in early October 2026.

1
The platform technology evaluation agreement with Eli Lilly, signed on October 7, 2024, was amended from about 14 months to a maximum of 24 months, pushing the end date to October 7, 2026.
2
Reported results remain small in scale: 2025 revenue of KRW 5.63bn with an operating loss of KRW 21.3bn, and operating cash flow has been negative for four consecutive years.
3
The Osong Plant 2 project carries a total investment of KRW 89.0bn; a construction contract with GC Biopharma EM was announced on September 3, 2026, and the investment period end date was moved to February 15, 2028.
4
In its own pipeline, PT403, a monthly semaglutide formulation, filed a Phase 1 IND with Korea's MFDS in August 2026, moving toward clinical entry.
5
Commercialized output is effectively limited to a single long-acting product for which LG Chem holds domestic marketing rights, leaving demand to fill the new plant's capacity as the key open question.

Business structure

Peptron is a KOSDAQ-listed biotech whose core assets are peptide drugs and a long-acting injectable formulation platform.

Its key technology, SmartDepot, is a drug delivery platform that encapsulates drugs in microspheres based on the biodegradable polymer PLGA to sustain efficacy over long periods, and it aims to release the drug gradually after injection so that efficacy is maintained for one to six months.

Revenue is a blend of small product and service sales plus R&D-related income, so it does not resemble a manufacturer with one dominant segment. The only product it has commercialized itself is Loofone, for which LG Chem holds exclusive domestic marketing rights.

In October 2025 it shipped the first commercial production batch of Loofone, a one-month long-acting prostate cancer treatment, and as LG Chem launched Loofone for precocious puberty, Peptron began commercial manufacturing at its Osong facility.

On partnerships, the pivotal arrangement is a contract granting Eli Lilly a non-exclusive license for joint research applying the SmartDepot platform to peptide drugs held by Lilly.

In its own pipeline, PT403, a monthly semaglutide formulation, is the lead asset, while PT320 for Parkinson's disease failed to reach statistical significance in a domestic Phase 2 trial and follow-up development was halted.

On the competitive map, it is frequently noted that Lilly has also partnered with Sweden's Camurus on long-acting formulations, and Camurus generates annual revenue in the KRW 300bn range and net profit in the KRW 70bn range from commercialized products.

In short, Peptron is one of few players combining a formulation platform with cGMP manufacturing capability, yet its actual revenue base remains small relative to platform expectations.

Earnings trend

Quarterly revenue · Operating profit

₩1.4B-₩5B25Q2₩1.6B-₩6.2B25Q3₩1B-₩5.7B25Q4₩2B-₩5.8B26Q1₩1.4B-₩7.9B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩5.8B-₩15.2B2022₩3.3B-₩15.9B2023₩3.2B-₩16.5B2024₩5.6B-₩21.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩1.4B	-₩5B	−349.2%
2025Q3	₩1.6B	-₩6.2B	−389.3%
2025Q4	₩1B	-₩5.7B	−576.4%
2026Q1	₩2B	-₩5.8B	−293.8%
2026Q2	₩1.4B	-₩7.9B	−549.9%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩5.8B	-₩15.2B	-₩15.1B	−261.9%	−28.4%	28.6%
2023	₩3.3B	-₩15.9B	-₩15.9B	−475.3%	−44.1%	45.3%
2024	₩3.2B	-₩16.5B	-₩22B	−524.3%	−14.5%	11.3%
2025	₩5.6B	-₩21.3B	-₩13.8B	−377.3%	−9.7%	26.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

The reported numbers look typical of a company still in the R&D stage. 2025 revenue was KRW 5,634.8mn, up 78.8% from KRW 3,152.2mn in 2024, yet the operating loss widened from KRW 16.53bn to KRW 21.26bn, with an operating margin of minus 377.3%.

Revenue itself has oscillated between roughly KRW 3bn and 6bn (KRW 5,814.0mn in 2022, KRW 3,341.9mn in 2023, KRW 3,152.2mn in 2024, KRW 5,634.8mn in 2025), far short of the scale needed to absorb fixed costs and R&D spending.

Net loss attributable to owners narrowed to KRW 13.82bn in 2025 from KRW 22.03bn in 2024; since the operating loss actually grew, the smaller net loss points to non-operating items acting as a cushion. Cash generation remains negative.

Operating cash flow was minus KRW 11.72bn in 2022, minus KRW 10.97bn in 2023, minus KRW 12.77bn in 2024 and minus KRW 20.59bn in 2025, so outflows have grown. The balance sheet, by contrast, was transformed by capital raising.

Equity rose from KRW 36.13bn at end-2023 to KRW 151.71bn at end-2024 and stood at KRW 142.01bn at end-2025; against total liabilities of KRW 36.97bn, the debt-to-equity ratio was 26.0%, below the 45.3% of 2023.

Quarterly, revenue and operating loss moved from KRW 1,425.6mn and minus KRW 4.98bn in 2Q25, to KRW 1,601.7mn and minus KRW 6.24bn in 3Q25, KRW 987.3mn and minus KRW 5.69bn in 4Q25, KRW 1,966.6mn and minus KRW 5.78bn in 1Q26, and KRW 1,445.3mn and minus KRW 7.95bn in 2Q26.

The 2Q26 operating loss and the attributable net loss of KRW 7.71bn were the largest among the five quarters provided, and for the most recent four quarters (3Q25 through 2Q26) revenue totalled about KRW 6.0bn against a combined operating loss of roughly KRW 25.7bn.

Industry analysis

The end market is GLP-1 class obesity and diabetes therapeutics, where the competitive axis is shifting from magnitude of weight loss toward dosing convenience.

As competition to develop long-acting formulations with extended dosing intervals expands in chronic disease markets including diabetes and obesity, manufacturing and quality-control capability that bridges candidate development through to post-clinical commercial production is emerging as a key competitive factor.

Developers commonly argue that because repeat-dosing burden and gastrointestinal side effects are key challenges in the GLP-1 market that requires long-term treatment, a once-monthly formulation offers room for differentiation in patient convenience and treatment adherence.

Big pharma, however, is not limited to one option. Amid a trend of global big pharma securing long-acting formulation partners to win the obesity drug race, Lilly has also joined hands with Camurus as another long-acting formulation partner.

Several Korean companies also position themselves in long-acting formulations, and large players such as Pfizer were reported to be expanding Asian trials of Metsera's obesity candidate and accelerating a long-acting strategy.

Cyclically, underlying demand is in an early expansion phase, but for a formulation technology supplier the outcome hinges on adoption by a small number of big pharma partners, a concentration risk.

The industry repeatedly flags the structural gap that there have been no material-sized technology transfers to date and revenue is in the tens of billions of won, while the market has assigned a valuation in the trillions.

Outlook

The nearest verification point is the end date of the Lilly technology evaluation. On December 1, 2025 the company amended the evaluation end date from about 14 months to about 14 months with a maximum of 24 months, meaning the end date could extend to October 7, 2026.

Because it is a limited license with no fully paid-up royalty, whether a follow-on definitive agreement is signed remains the central issue. Management's messaging has been consistent that work is on track.

In a July 10, 2026 statement, Peptron said the joint research does not target only one commercialized product and is proceeding as planned across multiple molecules, including next-generation obesity and diabetes candidates and central nervous system assets.

However, the company said the molecules under study and the evaluation results cannot be disclosed due to contractual confidentiality, leaving outsiders unable to verify progress directly. Its own pipeline timeline has become more concrete.

On August 25, 2026 the company disclosed that it had filed for Phase 1 IND approval with the MFDS for PT403, a one-month semaglutide-based diabetes and obesity candidate, and the trial period is set at 12 months from the date of approval by the MFDS and the institutional review board at Chungnam National University Hospital.

Manufacturing infrastructure advanced a step with the builder selection.

On September 3, 2026 the company said it had signed a construction contract with GC Biopharma EM to begin Plant 2 construction in earnest, targeting completion in February 2028, and the investment period end date was changed from June 30, 2027 to February 15, 2028, with total investment unchanged at KRW 89.0bn.

Management states the plan is to secure infrastructure covering not only its own pipeline production but also clinical and commercial supply demand arising from expanded global partnerships.

Valuation

PER

—

PBR

28.2×

ROE

-15.0%

EPS

-₩883

BPS

₩5,573

Dividend per share

₩0

Peptron posted operating and net losses in each of the last four fiscal years, so earnings-based multiples cannot be calculated. That narrows the usable reference to net-asset-based metrics, and the shares currently trade at a premium of several times book value per share.

On the confirmed financials there is no dividend payment record, so there is no basis for a yield comparison, which makes benchmarking against dividend-paying large pharma names difficult. In effect, the valuation rests on expectations for platform royalties and a definitive license rather than on reported results.

On this point, thebell noted in a February 2026 article the contrast between the absence of material-sized technology transfers and revenue in the tens of billions of won versus a market capitalization in the trillions.

Given the wide gap between earnings-based metrics and market value, it is closer to the facts to view non-financial events, such as the Lilly evaluation outcome and in-house clinical progress, as the drivers of how multiples are interpreted.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Non-exclusive structure leaves room for partner expansion

The Lilly agreement is a non-exclusive license for joint research applying SmartDepot to peptide drugs held by Lilly.

Industry commentary has suggested that because the deal is non-exclusive, collaboration with other pharmaceutical companies remains possible and there is meaningful demand to apply SmartDepot to candidates held by global partners.

The company says it is running joint development and commercialization discussions with multiple global pharmaceutical firms in parallel. At the same time, it should be noted that apart from Lilly, no partnership has been made concrete through disclosure.

Commercial production experience and infrastructure progress

The October 2025 shipment of the first commercial batch of Loofone, a one-month long-acting prostate cancer treatment, has been cited as evidence that SmartDepot has reached commercially viable technical competitiveness.

On capacity, the company is building a dedicated long-acting injectable plant meeting FDA cGMP standards on a 5,000-pyeong idle site in the Osong advanced medical complex, with capacity of up to 10 million vials a year and investment raised to KRW 89.0bn.

GC Biopharma EM, selected as builder on September 3, 2026, has experience in over 500 projects in GMP plants and bio research facilities. Few domestic players can offer both formulation technology and manufacturing.

In-house candidate PT403 entering the clinic

PT403 is a long-acting injectable applying SmartDepot to semaglutide, developed with the goal of extending the existing weekly dosing interval to once monthly.

Preclinical and pilot clinical data were presented at the American Diabetes Association meeting in June 2026; in the pilot, 16 healthy adults were split into eight receiving a single dose of PT403 and eight receiving conventional semaglutide to examine early pharmacokinetics, safety and tolerability.

The domestic Phase 1 is designed as a randomized, placebo-controlled, double-blind study in 22 subjects at Chungnam National University Hospital. As an in-house asset that could reduce partner dependence, its progress warrants monitoring.

Bear factors

Mismatch between earnings capacity and investment scale

Confirmed 2025 revenue of KRW 5,634.8mn against an operating loss of KRW 21.26bn is not a level at which a KRW 89.0bn capex programme can be funded from internal cash flow. It was reported that the disclosed investment equals 246.35% of shareholders' equity.

Operating cash flow was minus KRW 20.59bn in 2025, a larger outflow than minus KRW 12.77bn a year earlier.

Concerns have been raised over whether alternative demand exists to fill the utilization of a KRW 89.0bn facility if the Lilly definitive agreement does not materialize, and that the plant could sit idle unless such demand becomes visible by mid-2027.

Repeated schedule changes and communication controversy

The evaluation timeline was extended from about 14 months to a maximum of 24 months via an amended disclosure on December 1, 2025, and the plant schedule was likewise pushed out: in December 2025 investment was raised from KRW 65.0bn to KRW 89.0bn and the completion date moved from December 27, 2026 to June 30, 2027, then changed again in September 2026 to February 15, 2028.

It was also noted that the schedule changed only two months after the company said in July 2026, while addressing market concerns, that it was targeting a groundbreaking by September at the latest.

The disclosure approach itself drew criticism, as the Korea Economic Daily reported that the contract specified 24 months from the outset while only 14 months was disclosed, prompting an exchange request for correction.

Competing partners and information asymmetry

During the evaluation period, Lilly also partnered with Camurus on long-acting formulations.

On July 9, 2026, CEO Choi Ho-il said the joint research with Lilly involves a different peptide formulation and does not include tirzepatide, and added that tirzepatide-related joint work appeared to be with Camurus, which amplified the controversy.

The company explained that the remarks were a personal view based on public information and did not represent confirmation or an official judgement about another company's contract. The confidentiality structure, which prevents investors from verifying progress directly, is itself a source of such volatility.

Risk factors

Contract conversion risk

The license granted to Lilly is a limited, non-exclusive arrangement with no fully paid-up royalty, and whether a follow-on definitive agreement is signed is the central issue.

A technology evaluation agreement is a stage for verifying platform applicability and differs in nature from a licensing-out deal that includes commercialization rights, upfront payments and milestones.

If the evaluation does not convert into a definitive agreement or is extended again, the expectation-based valuation logic comes up for review. The contract value also remains withheld from disclosure until October 7, 2034 at Lilly's confidentiality request.

Funding and dilution

At end-2025, equity stood at KRW 142.01bn against total liabilities of KRW 36.97bn, a relatively stable structure, but four consecutive years of negative operating cash flow coincide with a KRW 89.0bn capex programme.

Equity was reportedly boosted by a KRW 160.0bn capital raise carried out amid a sharp share price rise; if further funding needs arise, the chosen method could dilute existing shareholders or raise interest costs. If depreciation increases while revenue does not scale, the operating loss would also be affected. This is a phase for tracking capex execution pace and funding plans through disclosures.

Clinical and regulatory risk

PT403 is only entering Phase 1, an early study evaluating safety, tolerability and pharmacokinetics after a single dose in healthy adults. Whether subsequent dose cohorts proceed is decided after a safety review committee assesses safety and tolerability data from the prior cohort, leaving room for schedule slippage.

As precedent, PT320 for Parkinson's disease completed a domestic Phase 2 but failed to achieve statistical significance and follow-up development was halted. Early-stage trials must be assessed on the premise that both probability of success and timing are uncertain.

What to watch next

Around October 7, 2026
This is when the maximum 24-month window for the Lilly platform technology evaluation is reached. Whether it resolves into a definitive commercial license, another extension, or termination is the pivotal variable for the company's valuation narrative.
4Q 2026
This is the window to check MFDS approval of the PT403 Phase 1 IND and the timing of first dosing. The trial period is set at 12 months from the approval date, so approval timing anchors the whole schedule.
During November 2026
The 3Q 2026 quarterly report will show revenue trends, R&D expense, SG&A and the pace of cash burn. Since 2Q 2026 produced the largest operating loss among the five quarters provided, the direction of the loss is worth watching.
4Q 2026 through 2027
Actual construction progress and capital outlay pace at Osong Plant 2, whose investment period end date was changed to February 15, 2028, need to be tracked. Construction timing, investment amount and disbursement schedule have been flagged as variables that could change.
During March 2027
The FY2026 annual report will reveal the composition of Loofone-related product sales and R&D income, plus year-end cash and equity movements. It serves as the reference for checking financial headroom against the KRW 89.0bn investment plan.

Overall view

Peptron is the type of company where the distance between reported results and the value assigned by the market is unusually wide.

Its 2025 figures - revenue of KRW 5,634.8mn, an operating loss of KRW 21.26bn and operating cash flow of minus KRW 20.59bn - show a company that has yet to convert platform expectations into earnings.

Conversely, there is verified progress, such as the October 2025 shipment of the first commercial production batch of Loofone and the September 3, 2026 construction contract with GC Biopharma EM for Plant 2, targeting completion in February 2028.

The watch items for the next six to twelve months are clear: the conclusion of the Lilly technology evaluation, whose window extends to October 7, 2026, approval and initiation of the PT403 Phase 1, and the financial burden of executing the KRW 89.0bn investment.

The bullish case rests on the partner-expansion room left by the non-exclusive structure and in-house manufacturing capability; the bearish case rests on capex that is heavy relative to earnings capacity and on repeated schedule changes.

Both cases hinge on the same event - whether a definitive agreement is signed - so the appropriate approach is to track disclosures rather than treat unverified expectations as fact. This report is for informational purposes and contains no buy or sell recommendation or target price for any security.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.